Iradimed CORP Form 4 insider transactions

Director Hilda Scharen-Guivel of IRADIMED CORPORATION sold 3,000 shares of common stock at a price of $95.00 per share.

Roger E. Susi, CEO and Director of IRADIMED CORP, reported the sale of common stock totaling 2,669 shares, executed under a pre-arranged Rule 10b5-1 trading plan.

IRADIMED Corporation CEO Roger E. Susi sold 7,500 shares of common stock via a pre-arranged Rule 10b5-1 trading plan.

Iradimed Corp CEO Roger E. Susi reported the sale of common stock totaling over 6,000 shares across multiple transactions executed between May 18-19, 2026, under a pre-arranged Rule 10b5-1 trading plan.

Iradimed Corp CEO Roger E. Susi sold a total of 6,486 shares of common stock across multiple transactions on May 11th and 12th, 2026, under a pre-arranged Rule 10b5-1 trading plan.

Iradimed Corp's CEO, Roger E. Susi, reported the sale of common stock totaling 7,527 shares across multiple transactions executed between May 4th and May 5th, 2026, under a pre-arranged Rule 10b5-1 trading plan.

Roger E. Susi, CEO and Director of Iradimed Corp, reported the sale of common stock totaling over 7,000 shares across multiple transactions executed between April 27-28, 2026, under a pre-arranged Rule 10b5-1 trading plan.

Roger E. Susi, CEO and Director of Iradimed Corp, reported the sale of common stock totaling 5,304 shares through a pre-arranged Rule 10b5-1 trading plan.

Roger E. Susi, CEO and Director of IRADIMED CORP, reported the sale of common stock totaling over 7,500 shares through a pre-arranged Rule 10b5-1 trading plan.

Roger E. Susi, CEO and Director of IRADIMED CORP, reported the sale of common stock totaling 5,648 shares across multiple transactions executed on April 6th and 7th, 2026, under a pre-arranged Rule 10b5-1 trading plan.

IRADIMED's CEO, President, and Chairman, Roger E. Susi, sold common stock totaling 7,500 shares on March 30, 2026, under a pre-arranged 10b5-1 trading plan.

IRADIMED Corporation's CEO, Roger E. Susi, reported multiple sales of common stock totaling 7,500 shares in late March 2026, executed under a pre-arranged Rule 10b5-1 trading plan.

IRADIMED's CEO, President, and Chairman, Roger E. Susi, sold a total of 7,500 shares of common stock in mid-March 2026 under a pre-arranged trading plan.

IRADIMED Corporation's Chief Commercial Officer, Jeff Chiprin, was granted 1,150 Restricted Stock Units under the company's 2023 Equity Incentive Plan.

IRADIMED Corporation's Chief Financial Officer, John Glenn, was granted 8,907 restricted stock units under the company's 2023 Equity Incentive Plan.

IRADIMED Corp. Director Monty K. Allen sold 1,000 shares of common stock for $100.2563 per share on February 13, 2026, under a Rule 10b5-1 plan.

IRADIMED Corp's CEO, President, and Chairman, Roger E. Susi, sold 5,000 shares of common stock on January 26, 2026, through a pre-arranged 10b5-1 trading plan.

IRADIMED Corp's CEO, President, and Chairman, Roger E. Susi, sold 4,900 shares of common stock on January 20, 2026, through a pre-arranged 10b5-1 trading plan.

IRADIMED Corp's CEO, President, and Chairman, Roger E. Susi, sold 5,000 shares of common stock for approximately $487,268 through a pre-arranged 10b5-1 trading plan.

IRADIMED Corp's CEO, President, and Chairman, Roger E. Susi, reported the sale of 5,000 shares of common stock on January 5, 2026, executed under a pre-arranged Rule 10b5-1 trading plan.

IRADIMED Corp's CEO, President, and Chairman, Roger E. Susi, sold a total of 5,000 shares of common stock on December 29, 2025, through a pre-arranged 10b5-1 trading plan.

IRADIMED Corp's CEO, President, and Chairman, Roger E. Susi, sold 5,000 shares of common stock on December 22, 2025, under a pre-arranged 10b5-1 trading plan.

IRADIMED Corp's CEO, President, and Chairman, Roger E. Susi, sold 5,000 shares of common stock for approximately $484,000 through a pre-arranged trading plan.

IRADIMED Corporation's Director, Hilda Scharen-Guivel, was granted 1,026 restricted stock units under the company's 2023 Equity Incentive Plan.

IRADIMED Corporation's Director, James B. Hawkins, was granted 1,026 restricted stock units under the company's 2023 Equity Incentive Plan.

IRADIMED Corporation's Director, Monty K. Allen, was granted 1,026 restricted stock units under the company's 2023 Equity Incentive Plan.

IRADIMED Corp's Chief Commercial Officer, Jeff Chiprin, converted restricted stock units into common stock and sold a portion to cover tax obligations.

IRADIMED Director Hilda Scharen-Guivel converted 905 restricted stock units into common stock, increasing her direct beneficial ownership.

IRADIMED Director James B. Hawkins acquired 905 shares of common stock through the vesting and conversion of restricted stock units, increasing his beneficial ownership.

IRADIMED Corporation's CFO, John Glenn, reported sales of common stock and the exercise of restricted stock units on December 11, 2025, under a pre-arranged plan.